The Handbook of Radiopharmaceuticals

Azuwuike Owunwanne (Autor)

Buch | Softcover

236 Seiten

2012 | Softcover reprint of the original 1st ed. 1995
Springer-Verlag New York Inc.
978-1-4757-0416-7 (ISBN)

Titel ist leider vergriffen;
keine Neuauflage

Artikel merken

and biologie disposition of administered ra- The Handbook of Radiopharmaceuticals is in- tended to bring together the salient features diopharmaceuticals. In Part Two, we de- of the chemieal, biologie and radiopharmacy scribe and discuss the chemistry, practical aspects of radiopharmaceutieals. It is de- aspects of in-house preparation, quality signed for nuclear medicine technology stu- control testing, biologie behavior, uses and dosimetry of each radiopharmaceutieal. The dents, nuclear medicine and radiology residents, radiopharmacists, radiochemists, information on biologie behavior is derived physicians, physieists and other scientists mainly from human data. In Part Three, we with an interest in nuclear medicine, for discuss a system approach for good radio- whom the handbook will be a quick refer- pharmacy practiee. And in Part Four, rel- ence book. The book emphasizes: evant theoretical and practical information is given as appendiees. * the practieal aspects of preparation, To fully und erstand and appreciate quality control testing and dispensing of Chapter 1, we recommend prior knowledge radiopharmaceuticals (and therefore is a of radiation physies.
We have tried as much very useful tabletop reference manual for as possible to include all the available la test technologists and radiopharmacists); materials, but as is always the ca se we might * the interrelationship between the effects have missed out a few radiopharmaceuticals of chemistry and biology on the bio dis tri- that are currently und er development.

One Radiobiopharmaceutics.- 1 Preparation of radiopharmaceuticals.- Production of radionuclides.- Synthesis of the non-radioactive compound.- Reaction of the radionuclide with the non-radioactive compound.- References.- 2 Ideal characteristics of radiopharmaceuticals.- Availability and cost.- Preparation.- Biologic behavior.- Radionuclidic characteristics.- Hematology.- 3 Quality control of radiopharmaceuticals.- Biologic tests.- Physicochemical tests.- References.- 4 Design of radiopharmaceuticals.- Radionuclide.- Chemistry.- Biology.- Human studies.- Registration.- References.- 5 The fate of administered radiopharmaceuticals.- Membrane transport systems.- Distribution.- Elimination.- The quality of the radiopharmaceutical.- The health status of the patient.- References.- 6 Drug-radiopharmaceutical interactions.- Desired drug-radiopharmaceutical interaction.- Undesired drug-radiopharmaceutical interaction.- References.- Two Basic Aspects of Radiopharmaceuticals.- 7 Technetium-99m radiopharmaceuticals.- Technetium-99m pertechnetate (99mTcC4?).- Technetium-99m d,l-hexamethylpropyleneamine oxime (99mTc-d,l-HMPAO).- Technetium-99m l,l-ethylcysteinate dimer (99mTc-l,l-ECD).- Technetium-99m[N-(-2(lH-pyrolymethyl))-N’-(-4-pentene-3-one-2)ethane- 1,2-diamine] (99mTc-MRP 20).- Technetium-99m macroaggregated albumin (99mTc-MAA).- Technetium-99m human albumin microspheres (99mTc-HAMs).- Technetium-99m aerosols.- Technetium-99m red blood cells (99mTc-RBCs).- Technetium-99m heat-denatured red blood cells (99mTc-HD-RBCs).- Technetium-99m hexakis-2-methoxy-2-isobutyl isonitrile (99mTc-sestamibi).- Technetium-99m chloro-Cmethylboron (1-)-tris (2,2-cyclohexanedione dioxime) (99mTc-teboroxime).- Technetium-99m 1,2-bis [bis(2-ethoxyethyl)phosphino]ethane (99mTc-tetrofosmin).- Technetium-99m phosphorus compounds.- Technetium-99m colloids.- Technetium-99m colloid solid meals.- Technetium-99m iminodiacetate derivatives (99mTc-IDAs).- Technetium-99m diethylenetriaminepentaacetic acid (99mTc-DTPA).- Technetium-99m dimercaptosuccinic acid (99mTc-DMSA).- Technetium-99m glucoheptonate (99mTc-GHA).- Technetium-99m mercaptoacetyltriglycine (99mTc-MAG3).- Technetium-99m human serum albumin (99mTc-HSA).- Technetium-99m technegas.- References.- 8 Iodine radiopharmaceuticals.- Iodine-123/131 sodium iodide (Na123/131I).- Iodine-123/131 sodium o-iodohippurate (123/131I-o-IH).- Iodine-123 N-isopropyl-p-iodoamphetamine (123IMP).- Iodine-123N,N,N’-trimethyl-N’-[2-hydroxy-3-methyl-5-iodobenzyl]1,3-propanediamine (123I-HIPDM).- Iodine-123/131 m-iodobenzylguanidine (123/131I-mIBG).- Iodine-123 fatty acids.- Iodine-1316?-iodomethyl-l0-norcholest-5(l0)-en-3?-ol(131I-iodomethyl norcholesterol).- References.- 9 Group IIIA radiopharmaceuticals.- Gallium-67 citrate (67Ga citrate).- Indium-111 radiopharmaceuticals.- 111In diethylenetriaminepentaacetate (111In DTPA).- 111In oxine- or tropolone-leucocytes and platelets.- Thallium-201 thallous chloride (201TlCl).- References.- 10 Group VIA radiopharmaceuticals.- Selenium-75 6-methyl-selenomethyl-19-norcholest-5-(10)-en-3?-ol (75Se-selenomethyl norcholesterol).- References.- 11 Antibodies.- Types of radioactive antibodies.- 123/131I antibodies.- 111In antimyosin (111In-Am).- 111In anticarcinoembryonic antigen (111n-anti-CEA).- 111In antitumour-associated glycoprotein (111In-anti-TAG/B72.3).- References.- 12 Receptor radiopharmaceuticals.- The binding of radiopharmaceutical to receptor sites.- The receptor system.- The choice of radionuclide.- The choice of ligand.- Labeling process.- Optimum imaging time.- Iodine-123 (S)-(?)-3-iodo-2-hydroxy-6-methoxy-N-[l-ethyl-2-pyrrolidinyl) methyl] benzamide (123IBZM).- Indium-111 DTPA-D-Phe-1-octreotide (111In-octreotide).- References.- 13 Radioactive noble gases.- References.- 14 Positron emission tomographic (PET) radiopharmaceuticals.- Cyclotron produced.- Generator produced.- Fluorine-18 2-deoxy-2-fluoro-D-glucose (18FOG).- Oxygen-15-labeled oxygen, carbon dioxide and carbon monoxide (15O215O-CO215O-CO).- Nitrogen-13 ammonia (13NH3).- References.- 15 Non-imaging radiopharmaceuticals.- Chromium-51 red blood cells (51Cr-RBCs).- Cobalt-57/58 cyanocobalamin (57/58Co-vitamin B12).- Ferrous-59 citrate (59Fe citrate).- Selenium-75 taura-23-selena-25-homocholic acid (75Se-HCAT).- Iodine-125 human serum albumin (125I-HSA).- Iodine-125 fibrinogen (125-fibrinogen).- References.- 16 Therapeutic radiopharmaceuticals.- Phosphorus-32 chromic phosphate (32P-CrPO4) and sodium phosphate (32P-Na2HPO4).- Strontium-89 chloride (89SrCl2).- Samarium-153 ethylenediaminetetramethylene phosphonic acid (153Sm-EDTMP).- Rhenium-186 1,1-hydroxyethylidene diphosphonate (186Re-HEDP).- References.- Three Good Radiopharmacy Practice.- 17 Design of a radiopharmacy.- Premises.- Personnel.- 18 Quality assurance.- Performance checking of the dose calibrator.- Dispensing of radiopharmaceuticals.- Record keeping.- 19 Radiation protection and safety.- Personnel.- The patient.- References.- 20 Disposal of radioactive waste material.- Sewer dilution.- Decay in storage.- 21 Regulatory policies and practice.- Further reading for Part Three.- Four Appendices.- Appendix A List of equipment, chemicals and consumables required in a radiopharmacy.- Appendix B Decay factors of radionuclides useful for nuclear medicine procedures.- Appendix C Recommended adult doses.- Appendix D Recommended pediatric dose as a fraction of the adult dose.- Appendix F Conversion to SI units.- Appendix G Decay schemes for commonly used radionuclides.- Appendix H Physical properties and production modes of reactor-produced radionuclides.- Appendix I Physical properties and production modes of cyclotron-produced radionuclides.

Zusatzinfo	3 Illustrations, black and white; XIV, 236 p. 3 illus.
Verlagsort	New York, NY
Sprache	englisch
Maße	189 x 246 mm
Gewicht	499 g
Themenwelt	Schulbuch / Wörterbuch
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
	Naturwissenschaften
	Sozialwissenschaften
ISBN-10	1-4757-0416-X / 147570416X
ISBN-13	978-1-4757-0416-7 / 9781475704167
Zustand	Neuware